0.05).The amount of insulin in ZL group was significantly lower than that in the control group(P

Objective:To explore the calvarial critical size defect (CSD)in rats with type 2 diabetes mellitus(T2DM).Methods:T2DM model of SD rats(weighted 300-320 g)was induced by high fat and high sugar diet and low dose intraperitoneal streptozotocin (STZ)injection.The rats with T2DMand the normal controls were divided into 4 groups(n=3)respectively.Defects with the diame-ter(mm)of 2,3,4 and 5 were made on the central calvaria of each rat.General observation,X-ray examination and histological study were performed 8 weeks postoperatively.Results:In the T2DM group,only the defects of 2 mm diameter were healed completely,X-ray resistance and new bone formation were observed;the defects of 3,4 and 5 mm diameter were unhealed,X-ray transmission was observed and newly formed bone was insufficient.In the control group,the defects of 2,3 and 4 mm diameter were healed completely, X-ray resistance and new bone formation were observed;the defects of 5 mm diameter were unhealed,X-ray transmission was ob-served,newly formed bone was insufficient.Conclusion:The calvarial CSD of T2DM rat model can be defined as the defect with the diameter of 3 mm.

Proprotein convertase subtilisin/kexin type 9(PCSK9)inhibitors not only have good lipid-lowering effects,but also have pleiotropic effects such as improving cardiovascular outcomes,re-lieving anti-inflammation,relieving oxidative stress and improving vascular endothelium.In recent years,the continuous development of PCSK9 inhibitors provides new ideas for the treatment of cardio-vascular diseases.This article reviewed the pleiotropic mechanisms of PCSK9 inhibitors,especially on vascular endothelial function.

Proprotein convertase subtilisin/kexin type 9(PCSK9)inhibitors not only have good lipid-lowering effects,but also have pleiotropic effects such as improving cardiovascular outcomes,re-lieving anti-inflammation,relieving oxidative stress and improving vascular endothelium.In recent years,the continuous development of PCSK9 inhibitors provides new ideas for the treatment of cardio-vascular diseases.This article reviewed the pleiotropic mechanisms of PCSK9 inhibitors,especially on vascular endothelial function.